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Abstract
Background:  Recently we have reported membrane androgen receptors-induced apoptotic
regression of prostate cancer cells regulated by Rho/ROCK/actin signaling. In the present study we
explored the specificity of these receptors and we analyzed downstream effectors controlling
survival and apoptosis in hormone refractory DU145-prostate cancer cells stimulated with
membrane androgen receptor-selective agonists.
Results:  Using membrane impermeable conjugates of serum albumin covalently linked to
testosterone, we show here down-regulation of the activity of pro-survival gene products, namely
PI-3K/Akt and NF-κB, in DU145 cells. Testosterone-albumin conjugates further induced FasL
expression. A FasL blocking peptide abrogated membrane androgen receptors-dependent
apoptosis. In addition, testosterone-albumin conjugates increased caspase-3 and Bad protein
activity. The actin cytoskeleton drug cytochalasin B and the ROCK inhibitor Y-27632 inhibited FasL
induction and caspase-3 activation, indicating that the newly identified Rho/Rock/actin signaling may
regulate the downstream pro-apoptotic effectors in DU145 cells. Finally, other steroids or steroid-
albumin conjugates did not interfere with these receptors indicating testosterone specificity.
Conclusion: Collectively, our results provide novel mechanistic insights pointing to specific pro-
apoptotic molecules controlling membrane androgen receptors-induced apoptotic regression of
prostate cancer cells and corroborate previously published observations on the potential use of
membrane androgen receptor-agonists as novel anti-tumor agents in prostate cancer.
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Background
An increasing body of scientific evidence points to the
existence of two types of androgen receptors: (a) intracel-
lular androgen receptors (iARs) mediating genomic
androgen signals resulting in receptor dimerization,
nuclear translocation and subsequent activation of andro-
gen-specific target genes (reviewed in [1]) and (b) mem-
brane androgen receptors (mARs) triggering non-genomic
signals manifested within minutes of androgen binding
(reviewed in [2,3]). Although the exact molecular identity
of mAR still remains unknown, it is believed that mAR
may represent either (I) a pool of iAR targeted to the
plasma membrane and/or associated membrane struc-
tures (e.g. lipid rafts or caveolae) mediating rapid andro-
gen effects in the absence of transcriptional activity
(reviewed in [4]) or (II) an unknown G-protein coupled
receptor (GPCR) (or a receptor associated with a GPCR)
triggering a variety of iAR-independent signaling cascades.
These cascades typically result in increased intracellular
[Ca2+]i and inositol 1,4,5-triphosphate formation, are sen-
sitive to pertussis toxin inhibition [5,6] and cannot be
blocked by anti-androgens [7,8]. Rapid, non-genomic
androgen actions have been reported in various cell types
including macrophages and T cells [9,10], LNCaP [7],
T47D [11], MCF7 [12], DU145 [13], C6 [14], PC12 [15]
or VSMC cells [16].
We and others have recently characterized mAR-depend-
ent signaling events in prostate and breast cancer cell lines
[8,11,12,17]. Using non-permeable androgen derivatives
that do not bind to iAR, namely conjugates of testosterone
covalently linked to bovine serum albumin (testosterone-
BSA), we have specifically shown that activation of mAR
results in actin reorganization of iAR+/mAR+ LNCaP and
iAR-/mAR+ DU145 prostate cancer cell lines [8,17]. Fur-
thermore, we have shown that testosterone-BSA induces
apoptotic regression of LNCaP and DU145 cells in vitro
and in mouse xenografts in vivo [13,18]. Finally, testoster-
one-BSA suppresses cell motility and potentiates paclit-
axel-mediated cytotoxicity both in vitro and  in vivo
[12,18]. However, the specific pro-apoptotic molecules
controlling the mAR-induced apoptosis in prostate cancer
cells remained unknown.
In the present study we have analyzed the specificity of
mAR and the activity of downstream gene products play-
ing a prominent role in survival and apoptosis in DU145
prostate cancer cells. Our results show that testosterone-
BSA suppresses PI-3K activity, inhibits Akt function and
finally inactivates the pro-survival transcription factor NF-
κB. We further report mAR-dependent suppression in the
phosphorylation/inactivation of the pro-apoptotic Bad
protein, stimulation of FasL expression and induction of
caspase-3 activity. Taken together, our results provide new
mechanistic insight into specific mAR-dependent apopto-
sis of prostate cancer cells.
Materials and methods
Cell culture and transfections
The DU145 human prostate cancer cell line was obtained
from the American Type Culture Collection (Manassas,
VA) and was studied between passages 60 and 70. DU145
cells fail to respond to androgen treatment owing to the
expression of non-functional iAR [19], or to complete lack
of iAR according to other studies [20,21].
Preparation of steroid solution
Before each experiment testosterone-3-(O-carboxyme-
thyl) oxime-BSA, referred to as testosterone-BSA, dihy-
drotestosterone (DHT), estradiol-BSA and
dexamethasone (Sigma), were dissolved in serum-free
culture medium at a final concentration of 10-5 M. The
steroid-albumin conjugates-stock solutions were incu-
bated for 30 min at room temperature with 0.3% charcoal
and 0.03% dextran, centrifuged at 3000 × g and passed
through a 0.45 μm filter to remove any potential contam-
ination with free steroid. Testosterone-BSA, estradiol-BSA,
dexamethasone and DHT solutions were used at a final
concentration of 10-7 M throughout all studies. If not oth-
erwise stated all treatments and incubations with steroids
including apoptosis assays were performed in serum-con-
taining medium.
Measurement of F/G actin ratio by Triton X-100 
fractionation
The Triton X-100 soluble G-actin containing and insolu-
ble F-actin containing fractions of cells exposed to testo-
sterone-BSA and DHT were prepared as previously
described [22]. An increase of the triton-insoluble (F) to
triton-soluble (G) actin ratio is indicative of actin polym-
erization.
Immunoprecipitation and Western blot analysis
DU145 cells treated or not (control cells) with testoster-
one-BSA were washed twice with ice-cold phosphate-buff-
ered saline and suspended in cold lysis buffer containing
1% Nonidet P-40, 20 mM Tris (pH 7.4) and 137 mM
NaCl, supplemented with protease and phosphatase
inhibitors. Cleared lysates were pre-adsorbed with protein
A-Sepharose beads (Amersham) for 1 h at 4°C. Equal
amounts of the supernatants were subjected to immuno-
precipitation using an anti-phosphotyrosine (PY20) anti-
body (Santa Cruz Biotechnology) and protein A-
Sepharose beads. For immunoblot analysis the immuno-
precipitates and equal amounts of total protein extracts
were suspended in Laemmli's sample buffer and separated
by SDS-PAGE. For Fas ligand expression studies cells were
pretreated or not with 10-7 M cytochalasin B (Biomol
Research Laboratories, PA), or 10 μM Y-27632 (Calbio-Molecular Cancer 2008, 7:88 http://www.molecular-cancer.com/content/7/1/88
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chem), and stimulated with 10-7 M testosterone-BSA for
the time periods indicated in the figure legends.
Proteins were transferred onto nitrocellulose membranes
and blotted with rabbit polyclonal anti-PI-3K p85
(Upstate) (1:1000 dilution), rabbit polyclonal anti-phos-
pho-Akt Ser473, anti-phospho-Akt Thr308 or anti-Akt
(total) (Cell Signaling) (1:500 dilution), rabbit polyclo-
nal anti-Fas-L (Q20, Santa Cruz) (1:200 dilution), phos-
pho- and total Bad antibodies (Santa Cruz Biotechnology,
Santa Cruz, CA, USA, 1:1000 dilution). Secondary anti-
bodies used were horseradish peroxidase-conjugated anti-
mouse IgG (Chemicon), and horseradish peroxidase-con-
jugated anti-rabbit IgG (Immunotech, France). Then, the
membranes were exposed to Kodak X-Omat AR films. A
PC-based Image Analysis program was used to quantify
the intensity of each band (Image Analysis, Inc., Ontario,
Canada).
NF-κB Transcription factor Assay
A non-radioactive NF-κB p50/p65 Transcription Factor
Assay was used to detect specific transcription factor DNA
binding activity in nuclear extracts (Chemicon, San Diego,
CA, USA). A double stranded biotinylated oligonucle-
otide containing the consensus sequence for NF-κB bind-
ing (5'-GGGACTTTCC-3'), was mixed with cellular
(nuclear) extract pre-treated or not with 10-7 M cytochala-
sin B. After co-incubation the active form of NF-κB con-
tained in the nuclear extract binds to its consensus
sequence. Thereafter, the extract/probe/buffer mixture
was directly transferred to the streptavidin-coated plate.
The biotinylated double stranded oligonucleotide bound
by active NF-κB protein was immobilized, and any inac-
tive unbound material was washed away. The bound NF-
κB transcription factor subunits, p50/p65, were detected
with specific primary antibodies. An HRP-conjugated sec-
ondary antibody was then used for detection and quanti-
fication in a spectrophotometric plate reader. By loading
the same amount of total protein in each sample, we
ensured the exact normalization for all cases.
Measurement of apoptosis
APOPercentage apoptosis assay
DU145 cells (in RPMI 1640, supplemented with 25 mM
HEPES, 2 mM L-Glutamine and 10% FBS) were cultured
in 96-well plates for the APOPercentage apoptosis assay
(Biocolor Ltd., Belfast, Ireland). In the presence or
absence of 10-7 M flutamide (Sigma), cells were stimu-
lated or not with 10-7 M of the following steroids in
serum-supplemented medium: testosterone-BSA (Testo-
BSA), dihydrotestosterone (DHT), estradiol-BSA (E2-BSA)
and dexamethasone (DEXA) or 10-7 M BSA for 24 hours.
Untreated cells cultured in serum free medium were used
as positive control for the apoptotic response.
FACS analysis
DU145 cells (in RPMI 1640, supplemented with 25 mM
HEPES, 2 mM L-Glutamine and 10% FBS) were cultured
in 60 mm plates for FACS analysis and determination of
Fas expression levels. After pre-treatment with a mono-
clonal Ab to Fas, (Fas-blocking peptide, 805-C10-C100,
Alexis Biochemicals, Axxora LLC, San Diego, USA), cells
were stimulated or not with 10-7 M testosterone-BSA in
serum-supplemented medium for the time periods indi-
cated in the figure legends. Untreated cells cultured in
serum-free medium were used as a positive control for the
apoptotic response. At the end of the respective treatment
cells were harvested in PBS and stained with the Annexin
V-FITC Apoptosis Detection kit I (BD Pharmingen TM,
San Diego, CA) according to the manufacturer's instruc-
tions. They were analyzed within 1 h by flow cytometry
using a FACSArray Apparatus (BD Biosciences) and Cel-
lQuest (BD Biosciences) and ModFit LT (Verify software,
Topsham, MN) software.
Caspase-3 assay
The activity of caspase-3 was measured in whole cell
lysates pre-treated or not with either 10-7 M cytochalasin
B, or 10 μM Y-27632 and then stimulated with 10-7 M tes-
tosterone-BSA for the time periods indicated in the figure
legends, using the Clontech ApoAlert® Caspase Colorimet-
ric Assay kit according to the manufacturers' instructions.
Caspase-3 activity was determined by incubating lysates
with a caspase-3 substrate (the peptide DEVD conjugated
to the chromophor p-nitroaniline) for 2 h at 37°C. The
absorbance of each sample was measured at 405 nm by
using a 96-well colorimetric plate reader.
Results
Testosterone and testosterone-albumin-conjugates trigger 
similarly specific activation of mAR in DU145 cells
As previously reported, DU145 cells are iAR-negative and
express functional mAR [13,17,19]. Accordingly, we have
evaluated early and late effects following mAR-activation
by using both, free testosterone and testosterone albumin
conjugates. Since actin reorganization is a main early cel-
lular response triggered by testosterone-BSA in various
tumor cell types [7,12,17], we first compared the rapid
alterations of actin polymerization dynamics in testoster-
one-BSA- and DHT-treated DU145 cells. As shown in Fig-
ure 1A, DHT induced rapid-within 5 minutes- and
sustained F/G-actin ratio increase, indicative for potent
actin polymerization, exactly as shown for testosterone-
BSA-treated DU145 cells (Fig 1A and ref. [17]). The F/G-
actin ratio-increase kinetics (Fig 1A) were comparable for
free and albumin-conjugated testosterone, indicating sim-
ilar mAR-activation potential by DHT and testosterone-
BSA. We have further evaluated the apoptosis of DU145
cells stimulated by DHT and testosterone-BSA. As shown
in Figure 1B both androgen analogs induced similar apop-Molecular Cancer 2008, 7:88 http://www.molecular-cancer.com/content/7/1/88
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totic responses. As expected for an iAR-negative cell line,
this effect was not abolished in the presence of the iAR
antagonist flutamide in DU145 cells. Moreover, BSA itself
was ineffective (Fig 1B). From these findings we can rule
out nonspesific testosterone-BSA-induced mAR stimula-
tion. Finally, we evaluated the steroid-hormone specificity
of the mAR-induced apoptotic responses in DU145 cells.
For this, we studied the induction of apoptosis by using
Modulation of the dynamic equilibrium between G- and F- actin and induction of apoptosis in testosterone-BSA stimulated  DU145 cells Figure 1
Modulation of the dynamic equilibrium between G- and F- actin and induction of apoptosis in testosterone-
BSA stimulated DU145 cells. A) 24 h serum starved cells were stimulated with 10-7 M testosterone-BSA or DHT for the 
indicated time points. F- and G- actin were measured by quantitative immunoblot analysis after Triton X-100 subcellular frac-
tionation. Bars represents the F/G actin mean value ± SE of three independent duplicate experiments (*P < 0.05). B) APOPer-
centage Apoptosis Assay of steroid-stimulated DU145 cells in the presence or absence of androgen receptor antagonist, 
flutamide (F). Cells pre-treated or not with 10-7 M flutamide (F), were incubated with testosterone-BSA, dihydrotestosterone 
(DHT), estradiol-BSA (E2-BSA), dexamethasone (DEXA) or control BSA dissolved in serum-supplemented medium at a final 
concentration of 10-7 M for 24 hours. Cells serum starved for equal period of time served as a positive control for apoptosis. 
The mean OD measured at 550 nm ± SE of three independent experiments performed in triplicates was normalized to the 
mean OD ± SE of the untreated control (serum supplemented) cells. Results are presented in bars as percentage (%) of control 
cells taken as 100% (**P < 0.01).Molecular Cancer 2008, 7:88 http://www.molecular-cancer.com/content/7/1/88
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BSA-conjugated estradiol and free dexamethasone. As
shown in Fig. 1B, both steroid hormones could not gener-
ate any apoptotic response in DU145 cells, while testo-
sterone-BSA showed clear activity. Taken together these
results provide strong evidence that activation of mAR by
testosterone or testosterone-conjugates is specific, trigger-
ing early and long-term downstream cellular responses in
prostate cancer cells.
Testosterone-BSA induces long term inhibition of PI-3K 
activity in DU145 cells
In contrast to iAR+ LNCaP cells, testosterone-BSA-stimu-
lated iAR- DU145 cells fail to rapidly activate FAK/PI-3K
signaling [8,17]. To evaluate the long term activity of PI-
3K and its possible involvement in the apoptotic
response, we treated DU145 cells with 10-7 M testoster-
one-BSA for various time periods and evaluated the tyro-
sine phosphorylation activity of the p85 regulatory
subunit in IP-Western assays (Fig 2). Total cell lysates sub-
jected to Western blot analysis with p85 antibodies were
used as controls. Testosterone-BSA significantly inhibited
p85-activity already 2 h post stimulation (Fig 2A). Further
exploration of the time-dependent effect of testosterone-
BSA on PI3K activity showed almost maximal inhibition
within 12 h, which sustained up to 24 h (Fig 2B). These
results indicate that stimulation of DU145 cells by testo-
sterone-BSA results in long term dramatic suppression of
Long-term dephosphorylation/inactivation of PI-3K in DU145 cells Figure 2
Long-term dephosphorylation/inactivation of PI-3K in DU145 cells. Serum supplemented DU145 cells were stimu-
lated with 10-7 M testosterone-BSA for the indicated time periods (A: 0, 60 or 120 min and B: 0, 12 or 24 h). Following cell lysis 
equal amounts of proteins were immunoprecipitated (IP) with an anti-phosphotyrosine (pTyr) antibody. The tyrosine-phospho-
rylated as well as equal amounts of total lysates were immunoblotted (IB) with a specific antibody against the p85 subunit of PI-
3K. The immunoblots were analyzed by densitometry. The intensity of phosphorylated PI-3K bands was normalized to the 
intensity of the corresponding total PI-3K band. Blots show a representative experiment, while the relative fold decrease in 
(p85)PI-3K phosphorylation with that of untreated cells taken as 1 are shown in the chart. Each bar represents mean values ± 
SE of at least three independent experiments (**P < 0.01).Molecular Cancer 2008, 7:88 http://www.molecular-cancer.com/content/7/1/88
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PI-3K activity, a finding compatible with the reported
mAR-induced apoptosis of this cell model.
Testosterone-BSA inhibits long term Akt activity and 
induces Bad de-phosphorylation in DU145 cells
Akt/PKB is a serine/threonine kinase frequently activated
in prostate cancer by various mechanisms including phos-
phorylation by PI-3K or loss of expression/activity of the
PTEN tumor suppressor [23-25], reviewed in [26]. Acti-
vated Akt is a pro-survival factor controlling phosphoryla-
tion and activity of various pro-apoptotic gene products
including caspase 9 [27] and Bad [28]. Since PI-3K acti-
vates Akt/PKB by phosphorylation at both the catalytic
subunit (Thr 308) and its C-terminus (Ser 473) [29-31]
and mAR-induction suppresses long term PI-3K activity in
DU145 cells (Fig 2), we sought to identify the activity sta-
tus of Akt in cells treated with testosterone-BSA for differ-
ent time periods. Figure 3A shows that Akt(Ser473)
phosphorylation, although it remained unaffected in the
early phase, it decreased by almost 50% after a 2 h testo-
sterone-BSA treatment. Long-term incubation experi-
ments fully supported this finding. Indeed, Akt
phosphorylation at Thr 308 and Ser 473 is significantly
decreased starting from 2 h (Fig 3B), and is almost com-
pletely suppressed after 24 h testosterone-BSA treatment
(Fig 3C) following very similar kinetics to the (p85)PI-3K
inhibition. Taken together these results indicate that testo-
sterone-BSA down-regulates the activity of the PI-3K/Akt
pro-survival pathway in DU145 cells.
In agreement with the inhibition of Akt activity shown in
Fig 3 and based on the well-documented role of this
Long-term dephosphorylation/inactivation of Akt kinase in DU145 cells Figure 3
Long-term dephosphorylation/inactivation of Akt kinase in DU145 cells. DU145 cells were exposed to 10-7 M testo-
sterone-BSA for the indicated time periods: (A: 0, 5, 15, 30, 60 and 120 min), (B: 0, 1, 2, 6 h) and (C: 0, 12 and 24 h). The ratio 
of the cellular content of the phosphorylated (at Ser473 or Thr308 residues) versus the total isoform of Akt kinase was meas-
ured in cell lysates by Western blotting using specific antibodies for each form and was normalized to the corresponding ratio 
of control. Blots show a representative experiment, while the numbers below each lane correspond to the mean values ± SE 
from three independent experiments (*P < 0.05, **P < 0.01) indicating the fold-decrease in the phosphorylation level for the 
indicated time point normalized to the corresponding short- and long-term untreated controls, respectively.Molecular Cancer 2008, 7:88 http://www.molecular-cancer.com/content/7/1/88
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kinase in inactivating the pro-apoptotic function of Bad
via phosphorylation [28,32], we further analyzed the
activity of Bad. Figure 4 clearly shows that testosterone-
BSA treatment results in dephosphorylation/activation of
Bad following the same pattern as Akt [statistically signif-
icant reduction of phosphorylation begins at 2 h (Fig 4A),
reaching minimum levels of phosphorylated Bad at 24 h
(Fig. 4B)]. From this finding we conclude that Bad activa-
tion contributes to the testosterone-BSA-induced apop-
totic events in DU145 cells.
Testosterone-BSA suppresses NF-κB activity in DU145 
cells
NF-κB is normally localized in the cytoplasm as an inac-
tive complex through physical association with its inhibi-
tory molecule IκB (reviewed in [33]). Work from several
laboratories has determined a sequence of biochemical
events resulting in the ubiquitin-dependent degradation
of IκB proteins [34-36], translocation of NF-κB into the
nucleus and activation of anti-apoptotic and pro-inflam-
matory genes [37,38]. To address the functional implica-
tion of NF-κB in mAR-signaling, we treated DU145 cells
with 10-7 M testosterone-BSA for 1 h and measured NF-κB
activity using a kit based on NF-κB's nuclear translocation
as described in Materials and Methods. As becomes evi-
dent in Figure 5, testosterone-BSA treatment inhibits NF-
κB activity in DU145 cells in agreement with the capacity
of testosterone-BSA to induce apoptosis by down-regulat-
ing several pro-survival pathways in prostate cancer cells.
Interestingly, inhibition of NF-κB activity was abolished
in the presence of the actin-disrupting drug cytochalasin B
confirming the recently postulated regulatory role of actin
reorganization in mAR-induced apoptosis in prostate can-
cer cells [17].
Testosterone-BSA induces FasL expression in DU145 cells
Having established a clear role for testosterone-BSA in
suppressing the activity of PI-3K/Akt and NF-κB pro-sur-
vival pathways in DU145 cells, we sought to characterize
the mechanism of apoptotic induction by testosterone-
BSA. Since the CD95/FasL death pathway was recently
shown to be involved in testosterone-BSA-induced apop-
tosis in LNCaP cells [13], we further investigated whether
Fas receptor activation is evident in DU145 cells. Figure
6A, B shows Western blot analysis and corresponding
quantitative determinations of pro-apoptotic FasL protein
in DU145 cells treated with testosterone-BSA for 6 h. Our
results show a significant increase in FasL expression.
Interestingly, this induction was abolished in cells pre-
treated with the actin cytoskeleton disruptor cytochalasin
B (Fig 6A, compare lanes 3 and 5), or with the ROCK
inhibitor Y-27632 (Fig 6A, compare lanes 3 and 7), indi-
cating a regulatory role for actin and Rho/ROCK signaling
in FasL expression. To confirm the participation of the
Fas/FasL pro-apoptotic effectors in testosterone-BSA-
induced apoptosis, we measured its apoptotic effect in the
presence of a specific Fas blocking peptide. Although the
Fas blocking peptide was unexpectedly shown to induce
apoptosis on its own (eventually through interaction with
the Fas receptor), it completely reversed the apoptotic
effect of testosterone-BSA (Fig 7). These results suggested
that testosterone-BSA-mediated up-regulation of FasL and
the subsequent activation of Fas receptor by its ligand are
the predominant mechanisms regulating cell death in
DU145 cells. From these findings and the activation of
Testosterone-BSA induces activation of the pro-apoptotic Bad protein in DU145 cells Figure 4
Testosterone-BSA induces activation of the pro-apoptotic Bad protein in DU145 cells. DU145 cells were exposed 
for different time periods (A: 0, 1, 2, 6) and (B: 12 and 24 h) to 10-7 M testosterone-BSA (testo-BSA). The ratio of the cellular 
content of the phosphorylated versus the total form of Bad was determined in cell lysates by Western blotting using specific 
antibodies. Blots show a representative experiment, while results are presented as the mean values ± SE from three independ-
ent experiments normalized versus the corresponding short- and long-term untreated controls respectively (**P < 0.01).Molecular Cancer 2008, 7:88 http://www.molecular-cancer.com/content/7/1/88
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Bad evident in Fig 4, we concluded that FasL and Bad
mediate the testosterone-BSA-induced apoptotic events in
DU145 cells.
mAR-stimulation by testosterone-BSA triggers caspase-3 
activation in DU145 cells
To assess the participation of caspases as executors in
mAR-dependent cell death, we measured caspase-3 activ-
ity in testosterone-BSA-treated DU145 cells. As presented
in Fig 8A, activation of caspase-3 became evident within 2
h upon testosterone-BSA treatment, reaching maximal
activity after 3–5 hours. This effect was blocked by the cas-
pase-3 inhibitor DEVD-fmk, or in cells pre-treated with
cytochalasin B or with the ROCK inhibitor Y-27632 (Fig
8B). These results indicate that in mAR-stimulated DU145
cells, caspase-3 activation is mediated by actin redistribu-
tion through the Rho/ROCK pathway.
Discussion
Previous studies in prostate cancer cell lines have estab-
lished a clear role for membrane androgen receptors in
the induction of apoptotic responses via actin cytoskele-
Testosterone-BSA suppresses the activity of the transcription factor NF-κB, which is reversed by the actin inhibitor cytochala- sin B Figure 5
Testosterone-BSA suppresses the activity of the transcription factor NF-κB, which is reversed by the actin 
inhibitor cytochalasin B. DU145 cells grown in serum supplemented medium were exposed for 60 min to 10-7 M testoster-
one-BSA, or to 10-7 M cytochalasin B alone or in combination with testosterone-BSA. TNF-treated HeLa cells or serum sup-
plemented DU145 cells were used as positive controls, 24 h-serum starved DU145 cells as negative control respectively. At 
the end of the incubation NF-κB activity was measured as described in Materials and Methods. Results are normalized to NF-
κB activity in cells cultured in serum-free medium in the absence of steroids and are presented as the mean values ± SE of four 
independent experiments performed in triplicates (**P < 0.01 for testosterone-BSA treatment versus serum conditions, and #P 
< 0.01 for testosterone-BSA treatment alone versus testosterone-BSA treatment plus cytochalasin B).Molecular Cancer 2008, 7:88 http://www.molecular-cancer.com/content/7/1/88
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Testosterone-BSA induces FasL expression, which is inhibited by the actin cytoskeletal drug cytochalasin B and the specific  ROCK inhibitor Y-27632 Figure 6
Testosterone-BSA induces FasL expression, which is inhibited by the actin cytoskeletal drug cytochalasin B 
and the specific ROCK inhibitor Y-27632. (A) Cells were pre-treated (+) or not (-) with 10-7 M cytochalasin B (cyt B) or 
Y-27632 (10 μM) for 1 h, and then exposed (+) or not (-) to 10-7 M testosterone-BSA in serum supplemented medium. 24 h 
serum starved cells served as a positive control for apoptosis. (A) Representative experiment showing FasL expression levels 
determined by immunoblotting equal amounts of cell lysates with a specific anti-FasL antibody (upper panel). The membrane 
was then stripped and re-probed with a specific anti-actin antibody to ensure equal protein loading (lower panel). Immunoblots 
were analyzed by densitometry. The relative fold increase in FasL expression with that of untreated cells taken as 1 is shown in 
the chart. Each bar represents mean values ± SE of three independent experiments (**P < 0.01).Molecular Cancer 2008, 7:88 http://www.molecular-cancer.com/content/7/1/88
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ton reorganization [17]. Furthermore, it has been pro-
posed that specific mAR-activating ligands, namely
testosterone-serum albumin conjugates, may be devel-
oped as novel drug candidates for the treatment of mAR+
prostate tumors [17,18].
Using pharmacological inhibitors, dominant negative
alleles and various functional assays, we were able to iden-
tify in previous studies a series of key denominators of
mAR function in prostate cancer cell lines [8,17]. Specifi-
cally, we have identified a FAK/PI-3K/Rac/Cdc42 pathway
triggered by testosterone-BSA in LNCaP cells, resulting in
actin cytoskeleton reorganization [8]. In DU145 cells FAK
and PI-3K were shown to be constitutively active, and tes-
tosterone-BSA triggers actin rearrangements via a Rho/
ROCK/LIMK2/ADF-destrin signaling pathway [17]. Inter-
estingly, the same Rho/ROCK pathway operates in LNCaP
cells, downstream of FAK/PI-3K/Rac1 [17]. Finally, actin
cytoskeleton disrupting agents and ROCK inhibitors were
shown to block mAR-dependent apoptosis in both cell
lines, indicating that Rho/ROCK/actin signaling is a key
regulator of apoptotic responses [17]. However the iden-
tification of the specific downstream players implicated in
apoptosis remained unknown.
In the present work we characterized the specificity of
mAR by using a series of BSA-conjugated and free steroid
hormones, providing clear evidence for testosterone spe-
cificity. We further explored the mechanism of cell death
triggered by mAR-stimulation by analyzing the expression
and activity of several gene products and pathways
involved in the regulation of survival and apoptosis of
DU145 prostate cancer cells. Using testosterone-BSA as a
specific mAR ligand, we show here that mAR activation
results in almost complete down-regulation of the activity
of PI-3K, Akt and NF-κB in DU145 cells. Concurrently,
testosterone-BSA induces FasL expression, activates Bad
and up-regulates the activity of caspase-3, indicating that
mAR-stimulation affects prominent pro-apoptotic regula-
tors [39,40]. Importantly, these effects are blocked by
actin cytoskeleton disrupting agents or the ROCK inhibi-
tor Y-27632, providing additional evidence that actin
reorganization, shown to be a prominent event in mAR-
stimulated prostate cancer cells [Fig 1A and ref [7,8,41]],
and the newly identified Rho/ROCK signaling [17] con-
trol testosterone-BSA-induced apoptosis in DU145 cells.
These data further corroborate the hypothesis postulated
by several research groups that actin dynamics reorganiza-
tion is a key regulator of apoptotic responses (for reviews
Testosterone-BSA-induced apoptosis is inhibited in the presence of a specific Fas blocking peptide Figure 7
Testosterone-BSA-induced apoptosis is inhibited in the presence of a specific Fas blocking peptide. FACS analy-
sis of DU145 cells treated with 10-7 M testosterone-BSA (serum conditions), 10 μM of Fas blocking peptide (in serum free con-
ditions) and both of these in parallel (serum conditions). Cells cultured in serum or 24 h serum starved cells were used as a 
negative and positive control for apoptosis respectively. Cells were co-stained with Annexin V-FITC for apoptotic cells and the 
vitality marker propidium iodide (PI). Representative percentages of viable and apoptotic cells under each condition are pre-
sented in the table.Molecular Cancer 2008, 7:88 http://www.molecular-cancer.com/content/7/1/88
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Testosterone-BSA induces Caspase-3 activation Figure 8
Testosterone-BSA induces Caspase-3 activation. A) Caspase-3 activity was measured at 405 nm in lysates derived from 
cells exposed to 10-7 M testosterone-BSA for the indicated time points and then incubated with the caspase-3 substrate DEVD 
conjugated to the chromophor pNA as described in Methods and Materials. B) Cells were pre-treated or not with 10-7 M of 
cytochalasin B or Y-27632 (10 μM) for 1 h and then exposed or not to 10-7 M testosterone-BSA for 3 h. The relative caspase-
3 activity is expressed as percentage with that of serum cultured cells taken as 100%. Data presented in bars are mean values ± 
SE of three independent experiments (*P < 0.05).Molecular Cancer 2008, 7:88 http://www.molecular-cancer.com/content/7/1/88
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see [42-44]). Taken together our results offer further
mechanistic insights into the control of survival and
apoptosis downstream of mAR, pointing to specific pro-
apoptotic molecular effectors acting most probably down-
stream of Rho/Rock/actin.
Although we cannot rule out that the observed changes in
the expression and activity of all analyzed proteins are the
consequence rather than the cause of mAR-dependent
apoptosis, the data clearly underscore the key role of
mAR-activating ligands in the selective elimination of
DU145 cells. Moreover, these receptors are specific for tes-
tosterone and testosterone-albumin conjugates, since
other steroid hormones-conjugated or not-failed to
exhibit any pro-apoptotic activity. Notably, these cells typ-
ically represent an aggressive pre-clinical hormone-refrac-
tory cell line model used to assess the anti-tumor ability
of chemotherapeutic drugs, as they (I) are devoid of func-
tional intracellular androgen receptors (iARs) and (II) fail
to respond to androgen treatment [19]. Based on these
results, mAR may be a novel target that can be used for the
selective elimination of mAR+ prostate cancer cells inde-
pendently of the functional status of the intracellular
androgen receptor. Interestingly, mAR is selectively over-
expressed in biopsy samples from aggressive, high-
Gleason prostate tumors in comparison to samples from
benign prostate hyperplasia patients or healthy subjects
[45,46].
Future experiments will focus on the identification of
additional signaling targets downstream of mAR and the
characterization of functional synergies of mAR-depend-
ent signals with other pathways activated in prostate can-
cer. Characterization of the functional interplay between
membrane and intracellular androgen receptors may con-
tribute to the understanding of the apparent discrepancy
in the actions of androgens inducing both proliferation
and death within a given cell. Our present findings eluci-
dating at least parts of the mAR-induced molecular pro-
apoptotic machinery in DU145 cells provide novel
insights in membrane GPCR mediated non-genomic
androgen actions.
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